Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ansbert Gadicke Sells 59,277 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 59,277 shares of the company’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $0.89, for a total value of $52,756.53. Following the completion of the sale, the insider owned 4,924,566 shares of the company’s stock, valued at $4,382,863.74. This represents a 1.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Thursday, December 4th, Ansbert Gadicke sold 83,230 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $80,733.10.
• On Wednesday, December 3rd, Ansbert Gadicke sold 57,225 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total transaction of $49,785.75.
• On Monday, December 1st, Ansbert Gadicke sold 60,917 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $57,261.98.
• On Friday, November 28th, Ansbert Gadicke sold 20,277 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total transaction of $20,074.23.
• On Wednesday, November 26th, Ansbert Gadicke sold 60,733 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $59,518.34.
• On Tuesday, November 25th, Ansbert Gadicke sold 42,533 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total transaction of $39,130.36.
• On Monday, November 24th, Ansbert Gadicke sold 88,802 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $87,025.96.
• On Friday, November 21st, Ansbert Gadicke sold 64,331 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total transaction of $53,394.73.
• On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total transaction of $36,625.28.
• On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $62,344.56.

Werewolf Therapeutics Stock Down 1.4%

Werewolf Therapeutics stock traded down $0.01 during mid-day trading on Friday, reaching $0.98. 67,889 shares of the company were exchanged, compared to its average volume of 502,483. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The firm has a market cap of $47.67 million, a P/E ratio of -0.61 and a beta of 0.74. The business has a fifty day moving average of $1.40 and a 200 day moving average of $1.33. Werewolf Therapeutics, Inc. has a 12-month low of $0.60 and a 12-month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. Research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

HOWL has been the subject of several analyst reports. Citigroup reissued a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. JMP Securities decreased their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Bank of America cut their price target on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Finally, Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.75.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds have recently made changes to their positions in the company. MPM Asset Management LLC raised its stake in Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after acquiring an additional 25,688 shares during the last quarter. MPM Bioimpact LLC increased its holdings in shares of Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares during the period. Bank of America Corp DE raised its stake in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics during the second quarter worth about $409,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.